

References:

1. Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK. Potentially preventable strokes in high risk patients with atrial fibrillation who are not adequately anticoagulated. *Stroke* 2009;40:235-240.
2. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. Results from the national registry of atrial fibrillation. *JAMA* 2001;285:2864-2870.
3. Lip GYH, Nieuwlaat R, Pisters R, Lane D, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. The Euro Heart Survey on Atrial Fibrillation. *Chest* 2010;137:263-272.
4. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GYH, Manning WJ. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008;133:546S-592S.
5. Guidelines for the Management of Atrial Fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. *Eur Heart J* 2010;31:2369-429.
6. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns JH, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. *Chest* 2010;138:1093-1100.
7. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. *Circ* 2008;118:2029-2037.
8. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. *Arch Intern Med* 2007;167:239-245.
9. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadbol N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. *Arch Intern Med* 2010;170(16):1441.
10. Hylek E. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. *N Engl J Med* 2003;349:1019-1026.

11. Hart R et al. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Arch Intern Med* 2007;146:857-867.
12. The ACTIVE writing group on behalf of the ACTIVE investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial *Lancet* 2006;367:1903-12
13. ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. *NEJM* 2009;360:2066-2078.
14. Connolly S et al. Dabigatran vs warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1129-51.
15. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. *N Engl J Med* 2010;363:1875-6.
16. Canadian Pharmacists Association. E-Therapeutics+:e-CPS: drug Monographs Aspirin[®], Available at www.e-therapeutics.ca/cps.showMonograph.action?simpleMonographId=m069600 [accessed December 5, 2010]
17. Canadian Pharmacists Association. E-Therapeutics+:e-CPS: drug Monographs Plavix[®], Available at <https://www.e-therapeutics.ca/cps.showMonograph.action?simpleMonographId=m433900> [accessed December 5, 2010]
18. Canadian Pharmacists Association. E-Therapeutics+:e-CPS: drug Monographs Coumadin[®], Available at <https://www.e-therapeutics.ca/cps.showMonograph.action?simpleMonographId=m143200> [accessed December 5, 2010]
19. Ansel J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists. *Chest* 2008;133;6(Suppl):160S-198S.
20. Pradox[®] Production Monograph Revision October 26, 2010
21. Pradaxa[®] USA Product Monograph Revised 10/2010 available at: <http://bidocs.boehringer-ingenheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf> [accessed December 5, 2010]

22. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wiene W, Feuring M, Clemens A. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. *Thromb Haemost* 2010;103:1116-7.